The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
19-Apr-01
$10.0 billion
Target:
GKN plc
Acquiror:
Brambles Industries Ltd
(Industrial Services)
Advised Brambles on its merger with the industrial services division of GKN under a dual listed companies structure
16-May-02
$545 million
Target:
Go Fly Ltd
Acquiror:
easyJet plc
(majority owned by 3i plc)
Advised Go Fly, Europe’s No. 3 no-frills airline, on its sale to easyJet. The acquisition created Europe’s largest low cost airline.
15-Oct-04
$135 million
Target:
Akzo Nobel N.V.
Acquiror:
Nuplex Industries Ltd.
Advised Akzo Nobel N.V., a global leader in coatings, chemicals and pharmaceuticals, on the sale of its coating resins activities to Nuplex Industries Ltd.
27-Oct-04
$3.0 billion
Target:
Warner Chilcott PLC
Acquiror:
Waren Acquisition Limited
Advised Warner Chilcott on approaches received and on recommended proposed acquisition by Waren Acquisition Limited, a vehicle funded by DLJ Merchant Banking and J.P. Morgan Partners, later joined by Bain Capital Partners and Thomas H. Lee Partners
20-Oct-05
$NA
Target:
Drakkar Holdings SA (Adisseo Group)
Acquiror:
China National Chemical Corporation
Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market
28-Nov-05
$103 million
Target:
Akzo Nobel N.V.
Acquiror:
Hexion Specialty Chemicals Inc.
(Ink and Adhesive Resins business) Advised Akzo Nobel N.V., a global leader in coatings, chemicals and healthcare on the sale of its Ink and Adhesive Resins business to Hexion Specialty Chemicals Inc
20-Feb-06
$254 million
Target:
Textile Effects
Acquiror:
Huntsman Corporation
(division of Ciba Specialty Chemicals AG)
Advised Ciba Specialty Chemicals AG on the sale of its global Textile Effects business
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
10-Nov-06
$1.9 billion
Target:
John Laing plc
Acquiror:
Henderson Equity Partners
Advised John Laing plc, the leading UK infrastructure investor and developer, on a recommended cash offer
30-Mar-07
$1.2 billion
Target:
Initial Electronic Security Group
Acquiror:
United Technologies Corp.
(the electronic security division of Rentokil Initial plc)
Advised Rentokil Initial on the sale of its electronic security division to United Technologies Corp.
04-Jun-07
$2.9 billion
Target:
Slough Estates USA (subsidiary of Slough Estates plc)
Acquiror:
Health Care Property Investors
Provided oversight of the process and an informal second opinion to the senior management of Slough Estates plc
18-Jul-07
$NA
Target:
SF-Chem AG
Acquiror:
CABB GmbH
Sole advisor to CABB, a leading producer of monochloroacetic acid and related specialty intermediates, on the acquisition of SF-Chem, a manufacturer of chlorine and sulphur specialty intermediates
31-Jul-07
$491 million
Target:
DEUTZ Power Systems
Acquiror:
3i
Sole advisor to DEUTZ AG on the divestiture of its division DEUTZ Power Systems, a leading manufacturer of gas fired engines for decentralized power generation
11-Oct-07
$1.2 billion
Target:
Foseco plc
Acquiror:
Cookson Group plc
Advised Foseco plc, a provider of consumables to the Foundry and Steel industries, on a recommended cash offer from Cookson Group plc
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
08-Oct-08
$NA
Target:
MAN Ferrostaal AG
Acquiror:
International Petroleum Investment Company (IPIC)
Advised MAN AG in relation to its 70% sale of MAN Ferrostaal AG, a worldwide supplier of industrial services for the construction of large-scale industrial plants and machine supply, to International Petroleum Investment Company (IPIC)
12-Oct-08
$6.0 billion
Target:
Hapag-Lloyd AG
Acquiror:
Albert Ballin KG
Advised TUI AG, Europe’s largest tourism company, on its sale of its shipping division Hapag-Lloyd AG, one of the leading global container shipping companies
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
19-Mar-09
$349 million
Target:
Inchcape plc
Provided financial advice to Inchcape, the leading independent international automotive retailer, on its assessment of funding and strategic options, resulting in a significant rights issue to strengthen the balance sheet
05-Jul-09
$1.2 billion
Target:
Alcan Packaging’s Food Americas business (business unit of Rio Tinto plc)
Acquiror:
Bemis Company, Inc.
Advised Bemis Company, Inc., a global supplier of flexible packaging and pressure sensitive materials, on its acquisition of Alcan Packaging’s Food Americas business
16-Jul-09
$NA
Target:
Pension Trustees of Galiform PLC
Advised the Pension Trustees of the Galiform PLC Defined Benefit Pension Scheme to negotiate a revised schedule of payments to fund its deficit
29-Jul-09
$573 million
Target:
Rexam plc
Acted as Financial Adviser and Joint Sponsor to Rexam plc, a leading global consumer packaging group, on its rights issue
08-Oct-09
$455 million
Target:
Ladbrokes Plc
Acted as Joint Financial Adviser to Ladbrokes plc, a leading UK based betting and gaming company, on its rights issue
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company